NR-13634结核分枝杆菌、CDC1551、转座子突变体1106(MT0951、Rv0924c)(突变细菌)
产品图片
货号/SKU
NR-13634
货号/规格
EA
库存与交货期
3-8周
人民币价格
14000
试剂海关审批
A/B级风险物质只能直接使用人购买并持有实验室有效资质,其它询客服确认
国外采购
支持/部分限制一年内购买数量
厂牌
BEI Resources(ATCC)
产品基础信息
生物安全等级建议分类:美国、3
产品描述信息
NR-13634??Mycobacterium tuberculosis, CDC1551, Transposon Mutant 1106 (MT0951, Rv0924c)(Mutant Bacteria)|Mycobacterium tuberculosis|CDC1551, Transposon Mutant 1106 (MT0951, Rv0924c)|2°C to 8°C|NIH - TB Vaccine Testing and Research Materials ContractAcknowledgment for publications should read "The following reagent was obtained through BEI Resources, NIAID, NIH: Mycobacterium tuberculosis, Strain CDC1551, Transposon Mutant 1106 (MT0951, Rv0924c), NR-13634."|Quantity limit per order for this item is 1. This item can be ordered twice a year. Orders over this limit will be sent to NIAID for approval before shipment.
In 2002, TARGET (Tuberculosis Animal Research and Gene Evaluation Taskforce) was formed to enable the modeling of human tuberculosis in multiple animal species using defined protocols and testing defined mutants of M. tuberculosis. In addition to animal modeling activities, a library of intragenic transposon mutants has been created and characterized. M. tuberculosis, transposon mutant 1106 was created by disruption of a transport protein (NRAMP family) (MT0951, Rv0924c), of the wild-type strain CDC1551.
TARGET: Rv0924c
MT Number (JCVI): MT0951
TubercuList: Rv0924c
Orf Description: transport protein
Orf Size: 1290
POI: 1070
Additional information is available at Mycobacterium tuberculosis CDC1551 Transposon Mutant Library.
This mutant was developed by Lamichhane, et al. at the Center for Tuberculosis Research, The Johns Hopkins University School of Medicine, PubMed: 12775759.
Each tube contains a Lowenstein-Jensen (LJ) agar slant that was inoculated with 0.1 mL of bacterial culture and incubated 2 to 4 weeks at 37°C.
In 2002, TARGET (Tuberculosis Animal Research and Gene Evaluation Taskforce) was formed to enable the modeling of human tuberculosis in multiple animal species using defined protocols and testing defined mutants of M. tuberculosis. In addition to animal modeling activities, a library of intragenic transposon mutants has been created and characterized. M. tuberculosis, transposon mutant 1106 was created by disruption of a transport protein (NRAMP family) (MT0951, Rv0924c), of the wild-type strain CDC1551.
TARGET: Rv0924c
MT Number (JCVI): MT0951
TubercuList: Rv0924c
Orf Description: transport protein
Orf Size: 1290
POI: 1070
Additional information is available at Mycobacterium tuberculosis CDC1551 Transposon Mutant Library.
This mutant was developed by Lamichhane, et al. at the Center for Tuberculosis Research, The Johns Hopkins University School of Medicine, PubMed: 12775759.
Each tube contains a Lowenstein-Jensen (LJ) agar slant that was inoculated with 0.1 mL of bacterial culture and incubated 2 to 4 weeks at 37°C.
主要内容
此项目的每个订单数量限制为1.此项目每年可订购两次.在此限制上订单将在发货前发送到北欧批准. 目标(结核病形成动物研究和基因评估任务性),以使使用定义的方案和测试定义的 m的定义突变体来实现多种动物物种中的人结核病的建模.结核病.除了动物建模活动之外,已经产生并表征了一种腺体转座子突变体的文库. m.结核病,通过破坏野生型菌株CDC1551的转运蛋白(NRAMP家族)(MT0951,RV092C)的破坏来产生转座子突变体1106.目标:rv0924c mt编号(JCVI): mt0951 结核小组: rv0924c ORF描述:运输蛋白质 ORF大小:1290 /default.aspx"> peigscobacterium thberculosis cdc1551转座突变库. 该突变体是由Lamichhane等人开发的.在结核病研究中心,约翰霍普金斯大学医学院,PubMed: 12775759 .
厂牌介绍
BEI Resources 由美国国家过敏和传染病研究所 ( NIAID )成立,旨在为研究 A、B 和 C 类优先病原体、新兴传染病病原体、非病原微生物和其他相关微生物材料提供试剂、工具和信息到研究界。BEI Resources 获取、验证和生产科学家进行基础研究和开发改进的诊断测试、疫苗和疗法所需的试剂。通过将这些功能集中在 BEI Resources 中,可以监控科学界对这些材料的访问和使用,并确保试剂的质量控制。
除了为传染病界提供材料外,BEI Resources 还鼓励和支持研究人员和机构的材料存放。使用 BEI Resources存放材料对研究人员和研究社区有许多优势,包括安全存储、社区访问和分发;同时保护存款人的知识产权。只要有需要,BEI 资源库将作为研究人员的资源进行维护。您在 BEI Resources 的存款是一项有助于未来研究的长期投资。
BEI Resources 自 2003 年起由美国典型培养物保藏中心 (ATCC) 根据合同管理。2016 年 5 月, ATCC获得了一份为期七年的继续管理 BEI Resources的合同。合同范围已扩大到更全面的研究目录材料,包括由其他政府支持的研究项目存放的材料,将提供给生物防御和新兴传染病科学界。真菌、寄生虫、载体和其他相关材料已添加到现有的细菌、病毒和毒素试剂中,涵盖 NIAID A、B 和 C 类优先病原体和 NIAID 指定的新发传染病病原体和生物。
品牌标识
可能感兴趣的内容
2022-03-31
2022-04-01
2021-12-21
2021-12-13
2021-12-21
2024-05-19
2022-04-01
2024-05-19
2021-12-02
2022-04-01
2024-05-19
2022-04-01
2019-05-08
2021-12-21
2024-06-03